Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle PLC

Form 8.3 - The Vanguard Group, Inc.: LondonMetric Property PLC

Form 8.3 - The Vanguard Group, Inc.: Bodycote PLC

Form 8.3 - The Vanguard Group, Inc.: Beazley PLC

Cummins raises 2030 financial targets, announces large-engine capacity and product investments

ArcWest Exploration Inc. Announces Semi-Annual Reporting

PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario

International Frontier Resources Corporation and Kinjal Corporation Provide Transaction Update on Debt Facility, Proposed Mexican Asset Transactions and New Board Additions

FIDDLEHEAD RESOURCES ANNOUNCES REPRICING OF STOCK OPTIONS

Alexandria Marie Lopez of Maison Solutions Inc. Named 2026 LA Executive Awards Nominee

Grizzly Provides Geophysical Program Updates to Define Precious and Critical Minerals Targets at Its Greenwood Projects, BC Canada

Enbridge Inc. and Enbridge Pipelines Inc. Announce Debt Exchange Proposal

TVS Motor Company Ranked #1 Globally For Shareholder Value Creation In ‘Durable Consumer Goods’ By WirtschaftsWoche And Boston Consulting Group

Epic Gold Announces Share Consolidation

TNR Gold Announces Completion of CAN$4.2 Million Altius Strategic Investment

First Lithium Minerals Announces Private Placement of up to $6 Million

Nokia Corporation - Managers' transactions (Owczarek)

Intesa Sanpaolo S p A : joins £500m financing for Eni CCUS Holding

A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate